the neuro-oncology service of the university of california brain tumor research center conducted a nonrandomized phase ii study to evaluate , in patients with recurrent malignant glioma , the benefit of a four-drug combination ( bfhm ) consisting of carmustine ( 1,3-bis ( 2-chloroethyl ) -1-nitrosourea ) , 5-fluorouracil , hydroxyurea , and 6-mercaptopurine .
C0006118
the
C0007257
carmustine